Table 2.

Clinical, electrocardiographic, echocardiographic characteristics and treatment practices of the study cohort.

Characteristics	Number of patients with missing data	Overall study cohort n = 1004 % (95% C.I.)
NYHA functional Class	Nil
Class I		5.3% (4.0% 6.9%)
Class II		63% (59.8% 65.8%)
Class III		21.7% (19.2% 24.4%)
Class IV		10.1%
Angina	10	25.0% (22.4% 27.9%)
History of Syncope	Nil	9.85% (8.1% 11.9%)
Past CVA/peripheral embolism	Nil	2.3% (1.5% 3.5%)
Electrocardiogram	174
Atrial Fibrillation		13.6% (11.4% 16.2%)
Complete heart block		0.9% (0.4% 2.0%)
Left bundle branch block (LBBB)		33.1% (29.9% 36.5%)
Right Bundle branch block (RBBB)		4.0% (2.8% 5.7%)
QRS duration (mean±sd) milliseconds	245	107.1 ± 33.9
QRS duration (≥150 ms)		17.6% (15.0% 20.5%)
Echocardiography	Nil
LVEF (mean±sd)	Nil	29.3% ± 7.02%
LVEF ≤20%	Nil	13.6% (11.6% 16.0%)
LVEF (21%–30%)	Nil	40.08% (37.1% 43.3%)
LVEF ≥31%–40%)	Nil	46.2% (43.1% 49.4%)
TAPSE	389	17.6 ± 6.88
Right ventricular dysfunction	389	36.9% (33.1% 40.9%)
Right Heart Failure	204	25.5% (22.6% 28.8%)
Tricuspid regurgitation)	6	58.7% (55.5% 61.8%)
PAH (TR velocity≥3.0 m/s)	6	44.7% (40.5% 49.0%)
Severe Mitral Regurgitation	Nil	11.5% (9.7% 13.8%)
Moderate AR	Nil	6 (0.6% (0.2% 1.4%)
Severe Aortic stenosis	Nil	3 (0.3% (0.1% 1.0%)
E/e’ (≥15) yes	507	59% (54.5% 63.3%)
Blood biochemistry
Hyponatremia (≤134 meq/L)	194	11.6% (9.5% 14.1%)
Hyperkalemia (≥5.5 meq/L)	195	11.5% (9.5% 14.0%)
Hypokalemia (≤3.4 meq/L)	195	6.33% (4.8% 8.3%)
Hyperuricemia (≥7.0 mg/dl)	419	48.7% (44.6% 52.8%)
Hypocalcaemia (≤8.0 mg/dl)	430	17.4% (14.5% 20.8%)
Treatment
Beta-Blockers	187	81.3% (78.8% 83.7%)
Rennin angiotensin Aldosterone system	201	80% (73.3% 82.4%)
Mineralocorticoid receptor antagonist	239	76.2% (73.5% 78.8%)
Automatic intracardiac defibrillator	2	0.3% (0.1, 1.0%)
Cardiac resynchronization therapy	2	0.2% (0.0% 1.8%)

Abbreviations: LVEF; left ventricular ejection fraction, TAPSE; tricuspid annular peak systolic excursion, PAH; pulmonary artery hypertension.